What is HLS Therapeutics Inc.'s (HLS.TO) StockRank?

MoatMap's StockRank for HLS Therapeutics Inc. (HLS.TO) is 63/100, with a Hold signal. This is a composite score combining Quality (44), Value (55), and Momentum (53) factor ranks across MoatMap's 20,000+ stock universe.

Does HLS Therapeutics Inc. have an economic moat?

HLS Therapeutics Inc. (HLS.TO) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is HLS Therapeutics Inc. a buy, hold, or sell?

MoatMap's current signal for HLS Therapeutics Inc. (HLS.TO) is Hold, based on a StockRank of 63/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is HLS Therapeutics Inc. in?

HLS Therapeutics Inc. (HLS.TO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HLS.TO

HOLD

HLS Therapeutics Inc. · Healthcare · Canada · $100M · Avg Vol: $158K/d

StockRank

P/E (TTM)

—

ROE

-16.4%

D/E

0.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

COMPANY DESCRIPTION

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, and commercializing established or late-stage branded drugs for the North American market. The company's competitive moat is built on its exclusive rights to high-barrier, clinically proven therapies such as Clozaril for schizophrenia and Vascepa for cardiovascular risk reduction. It operates as a low-R&D-risk specialty pharma player with a highly focused, cash-generative product portfolio.

PRICE (1Y)-8.8%

SMA 50SMA 200

$3.01

RSI (14)

38.9

52W High

$4.07

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-5.2%38.9

ROE

-16.4%31.4

GP/Assets

28.8%63.2

Op. Margin

-17.2%27.2

FCF/Assets

14.5%92.9

Piotroski

375.1

Int. Cover

-0.8x35.2

D/E Ratio

0.78x20.0

Current Ratio

1.00x10.2

Value

P/E (TTM)

—N/A

EV/EBITDA

10.5x65.1

P/FCF

6.8x88.1

P/B

1.7x65.8

P/S

2.5x60.5

Div Yield

—N/A

Momentum

52W High %

74%63.9

RS 6M

-20%56.0

SMA 50/200

0.94x47.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+75%65.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$100M

P/E (Forward)

-41.2x

Gross Margin

71.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HLS.TO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
HLS.TO	HLS Therapeutics Inc.(you)	$100M	63	HOLD
DB.V	Decibel Cannabis Company Inc.	$50M	60	HOLD
RX.V	BioSyent Inc.	$112M	96	STRONG BUY
OGI.TO	Organigram Global Inc.	$138M	33	SELL
ACB	Aurora Cannabis Inc.	$181M	30	SELL
CRDL.TO	Cardiol Therapeutics Inc.	$123M	22	SELL
CRON.TO	Cronos Group Inc.	$994M	62	HOLD
NVRS.CN	Noveris Health Sciences Inc.	$64M	23	SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
CPH.TO	Cipher Pharmaceuticals Inc.	$291M	99	STRONG BUY

Peer medians: ROE -46.6% · P/E 14.3x · Gross margin 32.9%

HLS Therapeutics Inc. (HLS.TO) — Stock Score Summary

HLS Therapeutics Inc. (HLS.TO) has a MoatMap StockRank of 63/100 based on Quality (44/100), Value (55/100), and Momentum (53/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$3.01
Market Cap	$100M
P/E (Forward)	-41.21
Price/Book	1.68
Return on Equity	-16.4%
Return on Invested Capital	-5.2%
Debt/Equity	77.78
Gross Margin	71.0%
Operating Margin	-17.2%
Revenue Growth	1.9%
Free Cash Flow	$15M

HLS Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is HLS Therapeutics Inc.’s (HLS.TO) StockRank?: MoatMap’s StockRank for HLS Therapeutics Inc. (HLS.TO) is 63/100, with a Hold signal. It is a composite of Quality (44), Value (55), and Momentum (53) factor ranks across MoatMap’s 20,000+ stock universe.
Does HLS Therapeutics Inc. have an economic moat?: HLS Therapeutics Inc. (HLS.TO) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is HLS Therapeutics Inc. a buy, hold, or sell?: MoatMap’s current signal for HLS Therapeutics Inc. (HLS.TO) is Hold, based on a StockRank of 63/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is HLS Therapeutics Inc. in?: HLS Therapeutics Inc. (HLS.TO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).